Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atomoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.97 |
| ▸ | HTR2A | P28223 | 2/20 | 0.97 |
| ▸ | HTR2C | P28335 | 2/20 | 0.97 |
| ▸ | HRH1 | P35367 | 2/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.97 |
| ▸ | DRD3 | P35462 | 2/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.97 |
| ▸ | HTR2B | P41595 | 2/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.97 |
| ▸ | KLF10 | Q13118 | 2/20 | 0.97 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atomoxetine SCHEMBL2206798 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL1560986 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL122111 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL29528186 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL627231 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL5783906 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL29440242 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL341802 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL12047445 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL2209541 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111302958-B | Preparation method of optically pure (R) -N-methyl-3-phenyl-3- (o-tolyloxy) -propylamine hydrochloride | 合肥医工医药股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-111302958-A | Preparation method of optically pure (R) -N-methyl-3-phenyl-3- (o-tolyloxy) -propylamine hydrochloride | 合肥医工医药股份有限公司 | 2020-06-19 | — | — | CN | claimed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | claimed |
| US-12508315-B2 | Use of vitamin E TPGS as a taste masking agent for bitter drugs | HYLORIS DEVELOPMENTS SA (BE) | 2025-12-30 | — | — | US | disclosed |
| EP-4654949-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | Hyloris Developments SA (BE) | 2025-12-03 | — | — | EP | disclosed |
| US-20250345436-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | HYLORIS DEV SA (BE) | 2025-11-13 | — | — | US | disclosed |
| US-20250049925-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | HYLORIS DEVELOPMENTS SA (BE) | 2025-02-13 | — | — | US | disclosed |
| WO-2024156799-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | HYLORIS DEVELOPMENTS SA (BE) | 2024-08-02 | — | — | WO | disclosed |
| CN-114790146-B | Preparation method of 3- (methylamino) -1-aryl acetone | 河南省科学院高新技术研究中心 | 2024-03-29 | — | — | CN | disclosed |
| CN-117024288-A | Synthesis method of tomoxetine | 迪嘉药业集团股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116396176-A | Preparation method of small-granularity tomoxetine hydrochloride crystals | 山东达因海洋生物制药股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-1038644-A | Nuclear substituted 2-amino-1,2,3,4-tetralin class | LILLY CO ELI (US) | 1990-01-10 | — | — | CN | disclosed |
| EP-0343830-A2 | Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes | ELI LILLY AND COMPANY (US) | 1989-11-29 | — | — | EP | disclosed |
| US-4876282-A | ANTIDEPRESSANT, DIETETICS, ANTIALCOHOLISM AGENT | ELI LILLY AND COMPANY (US) | 1989-10-24 | — | — | US | disclosed |
| US-4868344-A | OPTICALLY PURE HALOALCOHOLS | ALDRICH-BORANES, INC. (US) | 1989-09-19 | — | — | US | disclosed |
| US-4847092-A | GELATIN CAPSULES | ELI LILLY AND COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0318233-A2 | Improvements in or relating to serotonin and norepinephrine uptake inhibitors | ELI LILLY AND COMPANY (US) | 1989-05-31 | — | — | EP | disclosed |
| US-4797286-A | GELATIN CAPSULES FOR DRUGS | ELI LILLY AND COMPANY (US) | 1989-01-10 | — | — | US | disclosed |
| EP-0288188-A1 | 1-Phenyl-3-naphthalenyloxy-propanamines | ELI LILLY AND COMPANY (US) | 1988-10-26 | — | — | EP | disclosed |
| CN-88102018-A | 1-Phenyl-3-naphthyloxypropylamine | — | 1988-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345436-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | TAS2R5, TAS2R10, TAS2R50 | SLC6A2 20/4885SLC6A4 12/4885CYP1A2 326/4885 |
| US-12508315-B2 | Use of vitamin E TPGS as a taste masking agent for bitter drugs | SLC6A4, SLC6A3, CHRM5 | SLC6A2 4/4885SLC6A4 1/4885CYP1A2 1143/4885 |
| US-20250049925-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | TAS2R5, TAS2R10, TAS2R50 | SLC6A2 20/4885SLC6A4 12/4885CYP1A2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.